Risk factors for sulfamethoxazole/trimethoprim‐induced severe cutaneous adverse reactions
Clinical & Experimental Allergy · 2024
DOI: 10.1111/cea.14470 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical & Experimental Allergy, 2024. Verfasst von Kanokkarn Pinyopornpanish und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology and Rheumatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Trimethoprim, Sulfamethoxazole Drug Combination. Die Arbeit nennt 7 Literaturangaben. Gefördert von: Faculty of Medicine Ramathibodi Hospital Mahidol University.
Abstract (Originalsprache)
evidenced by the adjusted OR of 92.15 (95% CI 3.59–2367.61, p = .006). This finding emphasizes the association between HLA-B*13:01 and SMX/TMP-induced DRESS in various conditions, not particularly HIV infection. SMX/TMP dosage is discovered to be an independent risk fac - tor for SMX/TMP-induced SCARs in this study. The average dose of SMX/TMP was significantly higher in the SCAR cases (3.35 ± 0.78 tablets/day) than in the controls (1.59 ± 0.26 tablets/day). Multivariate analysis revealed that the risk for SMX/TMP-induced DRESS increases significantly at an OR (95% CI) of 1.33 (1.04–1.70) for dose increments by each tablet/day ( p = .025). Some limitations of this study should be considered. The sam - ple size was small, as limited by the rarity of the SCARs. In vivo or in vitro tests were not performed to validate the culprit drug as SMX or TMP. More extensive, future studies are needed to validate these findings and determine the clinical utility of HLA gene testing in pre - dicting adverse reactions to SMX/TMP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Immunology and Rheumatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Division of Allergy Clinical Immunology, Department of Medicine, Chiangmai University Hospital, Chiangmai, Thailand.
- Department of Clinical Epidemiology and Biostatistics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Clinical Pharmacy Section, Pharmacy Division, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand.
ORCID-Profile: Wannada Laisuan
Förderung
- Faculty of Medicine Ramathibodi Hospital Mahidol University
Zitieren
APA
Pinyopornpanish, K., Chungcharoenpanich, A., Teepapan, P., Thadanipon, K., Ruangwattanachok, C., Lamrahong, P., Thongdee, N., Dechapaphapitak, N., Sukasem, C., Pongphaew, C., Jantararoungtong, T., Koomdee, N., & Laisuan, W. (2024). Risk factors for sulfamethoxazole/trimethoprim‐induced severe cutaneous adverse reactions. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14470
Vancouver
Pinyopornpanish K, Chungcharoenpanich A, Teepapan P, Thadanipon K, Ruangwattanachok C, Lamrahong P, et al. Risk factors for sulfamethoxazole/trimethoprim‐induced severe cutaneous adverse reactions. Clinical & Experimental Allergy. 2024. doi:10.1111/cea.14470
BibTeX
@article{Pinyopornpanish2024,
author = {Pinyopornpanish, Kanokkarn and Chungcharoenpanich, Apinya and Teepapan, Putthapon and Thadanipon, Kunlawat and Ruangwattanachok, Chulapha and Lamrahong, Pansa and Thongdee, Nattakirana and Dechapaphapitak, Nizchapa and Sukasem, Chonlaphat and Pongphaew, Chanamon and Jantararoungtong, Thawinee and Koomdee, Napatrupron and Laisuan, Wannada},
title = {Risk factors for sulfamethoxazole/trimethoprim‐induced severe cutaneous adverse reactions},
journal = {Clinical & Experimental Allergy},
year = {2024},
doi = {10.1111/cea.14470}
}
EUVIMED